Lymphoma hub
@lymphomahub.bsky.social
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia.
New publication 📝Phase III TRIANGLE analysis, published in Leukemia, shows ibrutinib + immunotherapy led to rapid MRD responses in younger patients with MCL at interim staging (CTC: 71% vs 57%).
Learn more: https://loom.ly/GJ4qRI8
#Lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/GJ4qRI8
#Lymphoma #lymsm #MedNews #MedEd
November 28, 2025 at 9:01 AM
New publication 📝Phase III TRIANGLE analysis, published in Leukemia, shows ibrutinib + immunotherapy led to rapid MRD responses in younger patients with MCL at interim staging (CTC: 71% vs 57%).
Learn more: https://loom.ly/GJ4qRI8
#Lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/GJ4qRI8
#Lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨
FDA grants priority review to sonrotoclax, a next-generation BCL-2i, for the treatment of adult patients with R/R MCL, following treatment with a BTKi.
Read more here: https://loom.ly/mysSoBs
#MedNews #lymsm #lymphoma
FDA grants priority review to sonrotoclax, a next-generation BCL-2i, for the treatment of adult patients with R/R MCL, following treatment with a BTKi.
Read more here: https://loom.ly/mysSoBs
#MedNews #lymsm #lymphoma
November 27, 2025 at 3:23 PM
🚨 NEWS 🚨
FDA grants priority review to sonrotoclax, a next-generation BCL-2i, for the treatment of adult patients with R/R MCL, following treatment with a BTKi.
Read more here: https://loom.ly/mysSoBs
#MedNews #lymsm #lymphoma
FDA grants priority review to sonrotoclax, a next-generation BCL-2i, for the treatment of adult patients with R/R MCL, following treatment with a BTKi.
Read more here: https://loom.ly/mysSoBs
#MedNews #lymsm #lymphoma
🚨 NEWS 🚨
The European Commission has approved liso-cel, a CD19-direct CAR T-cell therapy, for the treatment of patients with R/R MCL after ≥2 prior lines of systemic therapy, including a BTKi, based on results from the TRANSCEND-NHL-001 trial.
Read more: https://loom.ly/ywPLKCY
#lymsm #MedNews
The European Commission has approved liso-cel, a CD19-direct CAR T-cell therapy, for the treatment of patients with R/R MCL after ≥2 prior lines of systemic therapy, including a BTKi, based on results from the TRANSCEND-NHL-001 trial.
Read more: https://loom.ly/ywPLKCY
#lymsm #MedNews
November 26, 2025 at 5:05 PM
🚨 NEWS 🚨
The European Commission has approved liso-cel, a CD19-direct CAR T-cell therapy, for the treatment of patients with R/R MCL after ≥2 prior lines of systemic therapy, including a BTKi, based on results from the TRANSCEND-NHL-001 trial.
Read more: https://loom.ly/ywPLKCY
#lymsm #MedNews
The European Commission has approved liso-cel, a CD19-direct CAR T-cell therapy, for the treatment of patients with R/R MCL after ≥2 prior lines of systemic therapy, including a BTKi, based on results from the TRANSCEND-NHL-001 trial.
Read more: https://loom.ly/ywPLKCY
#lymsm #MedNews
During our latest steering committee meeting, Gareth Gregory chaired a discussion on Glofit-GemOx in patients with R/R DLBCL.
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
November 25, 2025 at 9:01 AM
During our latest steering committee meeting, Gareth Gregory chaired a discussion on Glofit-GemOx in patients with R/R DLBCL.
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
New publication 📝 Data from the real-world EarlyMIND study, published in Haematologica, found that tafasitamab + lenalidomide achieved a best ORR of 46.8%, with a CR rate of 29.0% in patients with R/R DLBCL.
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
November 24, 2025 at 10:30 AM
New publication 📝 Data from the real-world EarlyMIND study, published in Haematologica, found that tafasitamab + lenalidomide achieved a best ORR of 46.8%, with a CR rate of 29.0% in patients with R/R DLBCL.
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
During our latest steering committee meeting, Gareth Gregory discussed updated results from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
November 20, 2025 at 10:30 AM
During our latest steering committee meeting, Gareth Gregory discussed updated results from the phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
Learn more: https://loom.ly/YpxZNZM
#lymphoma #lymsm #MedEd #MedNews
🚨 NEWS 🚨
FDA approves epcoritamab in combination with rituximab + lenalidomide for patients with R/R FL, based on results from the phase III EPCORE FL-1 trial.
Read more: https://loom.ly/O0V3cM0
#lymphoma #lymsm #MedNews #MedEd
FDA approves epcoritamab in combination with rituximab + lenalidomide for patients with R/R FL, based on results from the phase III EPCORE FL-1 trial.
Read more: https://loom.ly/O0V3cM0
#lymphoma #lymsm #MedNews #MedEd
November 19, 2025 at 6:15 PM
🚨 NEWS 🚨
FDA approves epcoritamab in combination with rituximab + lenalidomide for patients with R/R FL, based on results from the phase III EPCORE FL-1 trial.
Read more: https://loom.ly/O0V3cM0
#lymphoma #lymsm #MedNews #MedEd
FDA approves epcoritamab in combination with rituximab + lenalidomide for patients with R/R FL, based on results from the phase III EPCORE FL-1 trial.
Read more: https://loom.ly/O0V3cM0
#lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨
The European Commission has approved a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/Rf_qpm8
#lymphoma #lymsm #MedNews #MedEd
The European Commission has approved a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/Rf_qpm8
#lymphoma #lymsm #MedNews #MedEd
November 19, 2025 at 6:03 PM
🚨 NEWS 🚨
The European Commission has approved a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/Rf_qpm8
#lymphoma #lymsm #MedNews #MedEd
The European Commission has approved a subcutaneous formulation of mosunetuzumab for the treatment of adult patients with R/R FL after ≥2 prior lines of systemic therapy, based on results from the GO29781 trial.
Read more: https://loom.ly/Rf_qpm8
#lymphoma #lymsm #MedNews #MedEd
🚨NEWS 🚨
EMA CHMP issued a positive opinion recommending approval of tafasitamab + rituximab + lenalidomide for the treatment of adult patients with R/R FL after ≥1 prior line of systemic therapy, based on results from the inMIND trial.
Read more https://loom.ly/EUivYVU
#Lymphoma #lymsm #MedNews
EMA CHMP issued a positive opinion recommending approval of tafasitamab + rituximab + lenalidomide for the treatment of adult patients with R/R FL after ≥1 prior line of systemic therapy, based on results from the inMIND trial.
Read more https://loom.ly/EUivYVU
#Lymphoma #lymsm #MedNews
November 17, 2025 at 4:54 PM
🚨NEWS 🚨
EMA CHMP issued a positive opinion recommending approval of tafasitamab + rituximab + lenalidomide for the treatment of adult patients with R/R FL after ≥1 prior line of systemic therapy, based on results from the inMIND trial.
Read more https://loom.ly/EUivYVU
#Lymphoma #lymsm #MedNews
EMA CHMP issued a positive opinion recommending approval of tafasitamab + rituximab + lenalidomide for the treatment of adult patients with R/R FL after ≥1 prior line of systemic therapy, based on results from the inMIND trial.
Read more https://loom.ly/EUivYVU
#Lymphoma #lymsm #MedNews
🚨NEWS 🚨
EMA COMP issued a positive opinion recommending orphan drug designation for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of CTCL.
Read more: https://loom.ly/NArRPq0
#Lymphoma #lymsm #MedEd #MedNews
EMA COMP issued a positive opinion recommending orphan drug designation for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of CTCL.
Read more: https://loom.ly/NArRPq0
#Lymphoma #lymsm #MedEd #MedNews
November 17, 2025 at 4:04 PM
🚨NEWS 🚨
EMA COMP issued a positive opinion recommending orphan drug designation for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of CTCL.
Read more: https://loom.ly/NArRPq0
#Lymphoma #lymsm #MedEd #MedNews
EMA COMP issued a positive opinion recommending orphan drug designation for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of CTCL.
Read more: https://loom.ly/NArRPq0
#Lymphoma #lymsm #MedEd #MedNews
New publication 📝 A study published in Blood Advances found that patients with WM who tolerate ibrutinib may transition to zanubrutinib without compromising safety or efficacy.
Learn more: https://loom.ly/hCtP-X4
#Lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/hCtP-X4
#Lymphoma #lymsm #MedNews #MedEd
November 17, 2025 at 9:01 AM
New publication 📝 A study published in Blood Advances found that patients with WM who tolerate ibrutinib may transition to zanubrutinib without compromising safety or efficacy.
Learn more: https://loom.ly/hCtP-X4
#Lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/hCtP-X4
#Lymphoma #lymsm #MedNews #MedEd
🚨 News 🚨
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
November 14, 2025 at 3:57 PM
🚨 News 🚨
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
@US_FDA grants 510(k) clearance to a novel automated mass‑spectrometry system to aid in diagnosis of multiple myeloma and related disorders, including #WaldenstromsMacroglobulinemia. The platform detects and isotypes M-proteins with high sensitivity.
Read more: https://loom.ly/V5rp6VU
New publication📝 Results from an analysis of PROs from the POLARIX trial, published in Blood, highlight the value of patient-centric tools alongside clinician assessments for evaluating treatment tolerability.
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
November 14, 2025 at 9:01 AM
New publication📝 Results from an analysis of PROs from the POLARIX trial, published in Blood, highlight the value of patient-centric tools alongside clinician assessments for evaluating treatment tolerability.
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/BB_Azos
#lymphoma #lymsm #MedNews #MedEd
🚨 NEWS 🚨
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
November 12, 2025 at 4:08 PM
🚨 NEWS 🚨
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
FDA grants RMAT designation to MB-105, a first-in-class autologous CD5-targeted CAR T-cell therapy, for the treatment of patients with CD5+ R/R T-cell lymphoma.
Read more: https://loom.ly/uy1jSxg
#lymsm #Lymphoma #MedNews #MedEd
New publication📝 Results from a phase Ib/II trial, published in the Journal of Clinical Oncology, show Glofit-Pola achieved 78.3% ORR in heavily pretreated R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy.
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
November 10, 2025 at 9:01 AM
New publication📝 Results from a phase Ib/II trial, published in the Journal of Clinical Oncology, show Glofit-Pola achieved 78.3% ORR in heavily pretreated R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy.
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/rC-uX7Y
#lymphoma #lymsm #MedNews #MedEd
Francesc Bosch discussed factors influencing fixed-duration BTKi + BCL-2i treatment selection for patients with CLL.
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
November 7, 2025 at 3:07 PM
Francesc Bosch discussed factors influencing fixed-duration BTKi + BCL-2i treatment selection for patients with CLL.
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
Listen here: https://loom.ly/rOxk8hM
#leusm #lymsm #MedNews #MedEd
New publication📝2-year follow-up results from the RELIANCE trial, published in The British Journal of Haematology, show that relma-cel was associated with a CR rate of 96.3% in patients with R/R FL.
Learn more: https://loom.ly/uiZeapw
#lymphoma #CART #lymsm #MedNews #MedEd
Learn more: https://loom.ly/uiZeapw
#lymphoma #CART #lymsm #MedNews #MedEd
November 7, 2025 at 11:01 AM
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
November 6, 2025 at 5:30 PM
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
New data 📝 Results from studies of real-world outcomes and CD19 expression following tafasitamab treatment in patients with R/R DLBCL may guide the sequencing of CD19-directed therapies in this patient population.
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
November 5, 2025 at 9:01 AM
New data 📝 Results from studies of real-world outcomes and CD19 expression following tafasitamab treatment in patients with R/R DLBCL may guide the sequencing of CD19-directed therapies in this patient population.
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/6s-ODz0
#lymphoma #lymsm #MedNews #MedEd
New publication 📝 Results from the phase II FIL_V-RBAC trial, published in Lancet Haematology, show venetoclax added to RBAC was associated with a 2-year PFS rate of 60% in older patients with high-risk MCL.
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
November 3, 2025 at 9:01 AM
New publication 📝 Results from the phase II FIL_V-RBAC trial, published in Lancet Haematology, show venetoclax added to RBAC was associated with a 2-year PFS rate of 60% in older patients with high-risk MCL.
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
Learn more: https://loom.ly/EiJNbmg
#lymphoma #lymsm #MedNews #MedEd
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? The Lymphoma Hub was pleased to speak to Francesc Bosch, University Hospital Vall d’Hebron, about the use of fixed-duration therapy in CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
October 31, 2025 at 12:04 PM
What factors influence BTKi + BCL-2i treatment selection for patients with CLL? The Lymphoma Hub was pleased to speak to Francesc Bosch, University Hospital Vall d’Hebron, about the use of fixed-duration therapy in CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
New publication 📝 Phase II/II ENRICH trial results, published in The Lancet, show ibrutinib + rituximab improves PFS vs immunochemotherapy in older patients with previously untreated MCL (HR, 0.69; 95% CI, 0.52–0.90; p = 0.0034).
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
October 31, 2025 at 9:01 AM
Francesc Bosch, University Hospital Vall d’Hebron, discussed factors influencing BTKi + BCL-2i treatment selection for patients with CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
October 29, 2025 at 11:02 PM
Francesc Bosch, University Hospital Vall d’Hebron, discussed factors influencing BTKi + BCL-2i treatment selection for patients with CLL.
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
New publication 📝 Results from the phase III SUNMO trial, published in the Journal of Clinical Oncology, show Mosun-Pola significantly improved PFS (11.5 vs 3.8 months) and ORR (70% vs 40%) vs R-GemOx in transplant-ineligible R/R LBCL.
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
Learn more: LymphomaHub.com
#lymsm #lymphoma #MedNews #MedEd
October 28, 2025 at 9:01 AM
New publication📝Phase II results, published in Blood, show zanubrutinib + rituximab + lenalidomide was associated with a 65% CR rate, 2-year PFS of 67.1%, and 2-year OS of 82.4% in patients aged ≥75 years with de novo DLBCL.
Learn more: LymphomaHub.com
#DLBCL #lymphoma #lymsm #MedNews #MedEd
Learn more: LymphomaHub.com
#DLBCL #lymphoma #lymsm #MedNews #MedEd
October 24, 2025 at 8:01 AM